Thursday 26 March 2020
A Consensus Statement on the use of Angiotensin Receptor Blockers and Angiotensin Converting Emzyme Inhibitors in relation to COVID-19 (Corona Virus Disease 2019)
There has been an unprecedented interest generated in the medical community and on social media around the interaction of Coronavirus (SARS-CoV2) and ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB), and whether these medications increase the risk of COVID-19.
We have explored the available evidence and based on this, we DO NOT advise patients on ACEi or ARB to change therapy. These commonly used medications confer benefits in patients with cardiovascular disease and diabetes should not be changed unless clinically indicated. The current evidence on COVID-19 and hypertension, and ACEi or ARB medication is inadequately adjusted and prone to bias, and therefore remains inconclusive.
Our recommendation to prescribed use of ACEi and ARBs is consistent with the viewpoint of numerous societies from around the world including the European Society of Cardiology, the International Society for Hypertension, European Renal Association and European Dialysis and Transplant Association.
Consensus statement on COVID-19 and ARBs/ACEi